

**Request under Freedom of Information Act 2000**

Thank you for your request for information which we received on Tuesday 23<sup>rd</sup> April 2024. I am pleased to confirm the following.

**Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.**

348

**Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:**

	Oct-23	Nov-23	Dec-23	Jan-24	Feb-24	Mar-24	TOTAL
ICD code = c90	56	90	55	53	47	47	348
Belantamab Mafodotin [Blenrep]	4	4	7	6	4	2	27
Bortezomib [Velcade] monotherapy or with dexamethasone	0	0	0	3	1	1	5
Bortezomib, thalidomide and dexamethasone [VTD]	0	0	0	0	1	1	5
Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)	6	5	5	4	4	4	28
Carfilzomib [Kyprolis] and dexamethasone	0	0	0	0	0	0	0
Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone	4	5	5	4	4	4	26
Daratumumab [Darzalex] monotherapy	3	3	3	2	3	3	17

Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)	16	15	16	15	14	15	91
Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)	0	0	0	0	0	1	1
Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone	0	0	1	1	3	4	9
Elranatamab	0	0	0	0	0	0	0
Idecabtagene vicleucel [Abecma]	0	0	0	0	0	0	0
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)	8	7	8	7	3	3	36
Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)	5	4	3	5	3	8	28
Lenalidomide [Revlmid] monotherapy	2	2	2	2	5	3	16
Lenalidomide [Revlimid] and dexamethasone	3	3	3	3	2	2	16
Pomalidomide [Imnovid] and dexamethasone	1	1	2	0	0	3	7
Selinexor and dexamethasone	0	0	0	0	0	0	0
Talquetamab	0	0	0	0	0	0	0
Teclistamab [Tecvayli]	0	0	0	0	0	0	0
Any other systemic anti-cancer therapy Thanks very much	0	0	0	0	0	0	0

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will

be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Co-ordinator  
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the  
'Re-use of Public Sector Information Regulations' and best practice.